Showing 4621-4630 of 5556 results for "".
- FDA Accepts Revance's BLA Resubmission for DaxibotulinumtoxinAhttps://practicaldermatology.com/news/fda-accepts-revances-bla-resubmission-for-daxibotulinumtoxina/2461167/The U.S. Food and Drug Administration (FDA) accepted Revance’s Biologics License Application (BLA) resubmission for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines. The FDA designated the BLA as a Class 2 resubmission, which has a six-mont
- Virtual Skin Cancer Symposium® + Symposium for Inflammatory Skin Disease® Coming Soonhttps://practicaldermatology.com/news/virtual-skin-cancer-symposium-symposium-for-inflammatory-skin-disease-coming-soon/2461166/The 2nd Annual Skin Cancer Symposium® + Symposium for Inflammatory Skin Disease® (SCS + SISD) will be held virtually June 10-12, 2022. Fifteen well-known speakers will deliver 15 hours of CME credit on topics such as BCC, SCC, melanoma, actinic keratosis, dermosc
- New Survey Reveals Negative Impact of Psoriasis on Mental Healthhttps://practicaldermatology.com/news/new-survey-reveals-negative-impact-of-psoriasis-on-mental-health/2461159/Arcutis Biotherapeutics, Inc. recently shared findings from the Skin Insights: Uncovering Psoriasis Survey, a national survey of 507 adults 18+ diagnosed with plaque psoriasis who are on topical treatments. The online survey was conducted by The Harris Poll and was designed to reveal insight
- Botox Cosmetic Turns 20!https://practicaldermatology.com/news/botox-cosmetic-turns-20/2461158/Allergan Aesthetics’ BOTOX Cosmetic (onabotulinumtoxinA) turns 20 on April 15, 2022. This date marks 20 years since the U.S. Food and Drug Administration (FDA) first approved the product to temporarily improve the look of moderate to severe glabellar lines, located between th
- Lack of Options for Darker Skin Types Hinder Use of Tinted Sunscreenshttps://practicaldermatology.com/news/tinted-sunscreens-lack-options-for-darker-skin-hindering-use/2461156/The lack of tinted sunscreen options for darker skin tones may discourage many people from using these products. This is the main message from a new analysis of consumer preferences of over-the-counter tinted sunscreen products. Sixty-two percent of tinted sunscreen products are only av
- Aquavit Submits NDA for New Neurotoxinhttps://practicaldermatology.com/news/aquavit-submits-nda-for-new-neurotoxin/2461141/Aquavit Pharmaceuticals, Inc. has submitted its IND for a new botulinum toxin (DTX-021) to the FDA for approval. The company also unveiled its development programs at the Annual meeting of the American Academy of Dermatology in Boston. DTX-021, a botulinum toxin type A drug intende
- Opzelura Shows Benefit in 52-Week Phase 3 Vitiligo Studyhttps://practicaldermatology.com/news/opzelura-shows-benefit-in-52-week-phase-3-vitiligo-study/2461139/New 52-week results from the pivotal Phase 3 TRuE-V clinical trial program evaluating Incyte's topical JAK1/JAK2 inhibitor ruxolitinib cream (Opzelura™) in adolescent and adult patients with nonsegmental vitiligo show that twice daily application was
- Janssen Launches VISIBLE Study of PsO in People of Colorhttps://practicaldermatology.com/news/janssen-launched-visible-study-of-pso-in-people-of-color/2461121/The Janssen Pharmaceutical Companies of Johnson & Johnson has initiated VISIBLE, a first-of-its-kind, large-scale prospective clinical study dedicated to people of color living with moderate to severe plaque and/or scalp psoriasis (PsO). VISIBLE will further evaluate the efficacy an
- Jeune Aesthetics Announces Positive Clinical Phase 1 Efficacy Results for KB301https://practicaldermatology.com/news/jeune-aesthetics-announces-positive-clinical-phase-1-efficacy-results-for-kb301/2461119/Aesthetics, Inc.’s KB301 demonstrated promise in proof-of-concept in the Phase 1 PEARL-1 study. Specifically, Cohort 2 of this trial evaluated KB301 for the improvement of fine lines and skin texture in the lower and upper cheek, and for improvement in skin thickness in
- DefenAge Receives Two US Patents For Melasma and Hair Growthhttps://practicaldermatology.com/news/defenage-receives-two-us-patents-for-melasma-and-hair-growth/2461118/The US Patent and Trademark Office has granted two new patents to Defanage Skincare for the use of Defensin-molecules for topical treatment of hair loss in skin affected by alopecia and of the hyperpigmented lesions of melasma: &l